

Status of HPTN studies during COVID 19 pandemic

Ongoing Studies	Status: Enrolling	Status: Follow up	Status: Effective Immediately
Observational			
HPTN 083-02	Three sites are activated, no screening and enrollment. CPT and Thailand will be activated but no screening and enrollment		Screening and enrollment paused
Phase I			
HVTN127/HPTN 087		In follow-up through October. All infusions and injections have been completed.	Visit windows will be flexible, and will follow institutional policy
HVTN 130/HPTN 089		In follow-up – all infusions complete 3 in follow-up with their 2 nd infusion imminent (see comments)	The earliest allowable date for this infusion visit for all three of these people are this week or next week – sites can try to complete it if institutional policy allows
HVTN 136/HPTN 092	No sites activated		Screening and enrollment paused
HPTN 083-01	One site activated		Screening and enrollment paused
HPTN 084-01	No sites activated		Screening and enrollment paused

Interventional phase 2/3			
HPTN 083	Paused screening and enrollment at the small subset of non-US sites participating in the expanded enrollment; email has been sent to those sites	All sites have participants in follow-up; follow-up visit guidance provided by study leadership	Screening and enrollment paused at the small subset of non-US sites participating in the expanded enrollment
HPTN 084	Enrollment will be paused at sites in S. Africa and Eswatini	All sites have participants in follow-up in SA, Eswatini, Kenya, Malawi, Botswana, Uganda, Zimbabwe	Screening and enrollment paused in S. Africa and Eswatini Follow-up visit guidance provided by study leadership
HPTN 081 and HPTN 085		Anticipated final study product administration is May for 703/081; June for 704/085	Visit windows will be flexible, and will follow institutional policy
HVTN 804/HPTN 095	One site activated		Screening and enrollment paused